From Today's Press Release on $IVST The opportunities the Biotechnology Division will be pursuing involve highly complex concepts in a rapidly evolving market with life saving technologies. Dr. Morris-Irvin has been diligently laying the groundwork for the division for months and proudly introduces his colleagues and new Innovest Global team members; Introducing Dr. Laina King, Dr. Andrew Norris, Dr. Malin Parmar, and Dr. Lachlan Thompson (full biographies below).
“Dr. Morris-Irvin is one of the top scientists in the world in his field, and it takes such a person with his success characteristics to lead an effort of this magnitude. I’m so incredibly impressed by his diligence and the focused, long-term value mindset that we all share at Innovest. After a few months with him on the job I would argue that we have quite possibly one of the most qualified, the most connected and certainly one of the most equipped biotech teams in the country. On behalf of the entire Innovest family, we are honored by their contribution and thank and welcome them enthusiastically,” said Dan Martin, Innovest Chairman and Chief Executive Officer.
Biographies:
Dr. Laina King
Dr. Laina King is a management consultant, administrator, researcher, external grant reviewer and tenured professor with more than 15 years of administrative experience in the for-profit, not-for-profit, federal agency and academic environments. She obtained her doctoral and postdoctoral training at the University of Michigan, Harvard and the Coverdale Institute. Her past 5 years have been with the United States Department of Health and Human Services Food & Drug Administration (FDA/CDER & FDA/OEA) and National Institutes of Health Office of the NIH Director. Prior to these engagements, she was a senior administrator and Principal Investigator at Keystone Symposia on Molecular & Cellular Biology, Associate Academic Dean and Professor of Pharmaceutical Sciences in a college of pharmacy and a tenured Professor of Management at an AACSB school of business. Significant academic appointments include being a voting Member of the AMA/AAMC Liaison Committee on Medical Education (LCME), Commissioner at the North Central Association of Colleges & Schools and Steering Committee Member of the CDC Health Disparities Institute Development Group. Her research, national presentations and publications are in the areas of organizational behavior, advanced academic mentoring & positioning, graduate education training program implementation and operational management. She has authored numerous peer reviewed articles and book chapters and has edited a three volume book series on managed care. Her consulting experience includes work with the Military District of Washington, Japan Consultant for the Department of Defense, American Council on Education and multiple health care professional credentialing agencies.
Dr. Andrew Norris
Dr. Andrew Norris has a varied background in both business and the technology sector. He is Co-founder of The Midvale Group LLC in 2002, consulting in both the technology and biotechnology sector. Dr. Norris has also Co-founded BCN Biosciences in Pasadena CA (2005), which is a privately held biotechnology company whose principal focus is in the area of oncology drug development. Dr. Norris has been directly responsible for, or co-raised over $20M in funding for the technology and Biotechnology sector. He currently serves as an officer/director at BCN Biosciences and also holds a research faculty position at the University of California Los Angeles Department of Neuropsychiatry. Dr. Norris received his PhD from UCLA School of Medicine, Department of Molecular & Medical Pharmacology and Chemistry. His research focused on synthesizing molecular inhibitors against cancer cells. He also trained in the Surgical Oncology Department at UCLA focusing his research on novel drug discovery for breast cancer patients.
Dr. Malin Parmar
Dr. Malin Parmar is a Professor in cellular neuroscience at Lund University. Together with her lab she has shown in a series of high profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells. She is the recipient of an ERC starting grant and an ERC Consolidator grant and was recently awarded a New York Stem Cell Foundation – Robertson investigator. Her research has a strong translational focus and she collaborates within European and International networks as well as Industry partners to develop new, cell-based therapies for Brain Repair with focus on Parkinson’s Disease.
Dr. Lachlan Thompson
Dr. Lachlan Thompson, Associate Professor is a Principal Research Fellow at the Florey Institute for Neuroscience and Mental Health. He heads a research program dedicated to regenerative approaches to repair of the central nervous system, with a special focus on the use of pluripotent stem cells for functional reconstruction of circuitry affected in Parkinson’s disease, stroke and motor neuron disease. He has contributed more than 50 research papers on this topic in leading journals including the Journal of Neuroscience, Neurobiology of Disease, Proceedings of the National Academy of Science, Brain and Cell Reports. Dr. Thompson is a partner investigator in the Australian government’s major Stem Cells initiative where he sits on the committee for clinical translation and commercialisation and plays an active role in contributing to policy making on the regulation of experimental stem cell therapies. He also sits on the board of the Network for European CNS Transplantation and Repair and is president of the Asia-Pacific Association for Neural Transplantation and Repair. Dr Thompson brings a wealth of experience in cutting-edge technology driving pre-clinical research in regenerative approaches to brain repair and also in understanding of the regulatory frameworks governing clinical translation and commercialisation of stem cell therapies.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is a conglomerate with operations in three divisions, which include commercial and industrial products and services, energy, biotechnology, health sciences, construction, and building materials. The primary growth strategy of Innovest Global Inc is to acquire existing companies in a select few industries and attract new customers in cost effective ways. Currently, Innovest Global Inc has a Commercial & Industrial Division, a Biotechnology & Health Services Division, and a Construction & Building Materials Division.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter and Facebook @innovestglobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact Information
Corporate Office:
(216) 815-1122
info@innovestglobal.com
Twitter @innovestglobal
Investor Relations:
Hayden IR
(917) 658-7878
hart@haydenir.com
“Dr. Morris-Irvin is one of the top scientists in the world in his field, and it takes such a person with his success characteristics to lead an effort of this magnitude. I’m so incredibly impressed by his diligence and the focused, long-term value mindset that we all share at Innovest. After a few months with him on the job I would argue that we have quite possibly one of the most qualified, the most connected and certainly one of the most equipped biotech teams in the country. On behalf of the entire Innovest family, we are honored by their contribution and thank and welcome them enthusiastically,” said Dan Martin, Innovest Chairman and Chief Executive Officer.
Biographies:
Dr. Laina King
Dr. Laina King is a management consultant, administrator, researcher, external grant reviewer and tenured professor with more than 15 years of administrative experience in the for-profit, not-for-profit, federal agency and academic environments. She obtained her doctoral and postdoctoral training at the University of Michigan, Harvard and the Coverdale Institute. Her past 5 years have been with the United States Department of Health and Human Services Food & Drug Administration (FDA/CDER & FDA/OEA) and National Institutes of Health Office of the NIH Director. Prior to these engagements, she was a senior administrator and Principal Investigator at Keystone Symposia on Molecular & Cellular Biology, Associate Academic Dean and Professor of Pharmaceutical Sciences in a college of pharmacy and a tenured Professor of Management at an AACSB school of business. Significant academic appointments include being a voting Member of the AMA/AAMC Liaison Committee on Medical Education (LCME), Commissioner at the North Central Association of Colleges & Schools and Steering Committee Member of the CDC Health Disparities Institute Development Group. Her research, national presentations and publications are in the areas of organizational behavior, advanced academic mentoring & positioning, graduate education training program implementation and operational management. She has authored numerous peer reviewed articles and book chapters and has edited a three volume book series on managed care. Her consulting experience includes work with the Military District of Washington, Japan Consultant for the Department of Defense, American Council on Education and multiple health care professional credentialing agencies.
Dr. Andrew Norris
Dr. Andrew Norris has a varied background in both business and the technology sector. He is Co-founder of The Midvale Group LLC in 2002, consulting in both the technology and biotechnology sector. Dr. Norris has also Co-founded BCN Biosciences in Pasadena CA (2005), which is a privately held biotechnology company whose principal focus is in the area of oncology drug development. Dr. Norris has been directly responsible for, or co-raised over $20M in funding for the technology and Biotechnology sector. He currently serves as an officer/director at BCN Biosciences and also holds a research faculty position at the University of California Los Angeles Department of Neuropsychiatry. Dr. Norris received his PhD from UCLA School of Medicine, Department of Molecular & Medical Pharmacology and Chemistry. His research focused on synthesizing molecular inhibitors against cancer cells. He also trained in the Surgical Oncology Department at UCLA focusing his research on novel drug discovery for breast cancer patients.
Dr. Malin Parmar
Dr. Malin Parmar is a Professor in cellular neuroscience at Lund University. Together with her lab she has shown in a series of high profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells. She is the recipient of an ERC starting grant and an ERC Consolidator grant and was recently awarded a New York Stem Cell Foundation – Robertson investigator. Her research has a strong translational focus and she collaborates within European and International networks as well as Industry partners to develop new, cell-based therapies for Brain Repair with focus on Parkinson’s Disease.
Dr. Lachlan Thompson
Dr. Lachlan Thompson, Associate Professor is a Principal Research Fellow at the Florey Institute for Neuroscience and Mental Health. He heads a research program dedicated to regenerative approaches to repair of the central nervous system, with a special focus on the use of pluripotent stem cells for functional reconstruction of circuitry affected in Parkinson’s disease, stroke and motor neuron disease. He has contributed more than 50 research papers on this topic in leading journals including the Journal of Neuroscience, Neurobiology of Disease, Proceedings of the National Academy of Science, Brain and Cell Reports. Dr. Thompson is a partner investigator in the Australian government’s major Stem Cells initiative where he sits on the committee for clinical translation and commercialisation and plays an active role in contributing to policy making on the regulation of experimental stem cell therapies. He also sits on the board of the Network for European CNS Transplantation and Repair and is president of the Asia-Pacific Association for Neural Transplantation and Repair. Dr Thompson brings a wealth of experience in cutting-edge technology driving pre-clinical research in regenerative approaches to brain repair and also in understanding of the regulatory frameworks governing clinical translation and commercialisation of stem cell therapies.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is a conglomerate with operations in three divisions, which include commercial and industrial products and services, energy, biotechnology, health sciences, construction, and building materials. The primary growth strategy of Innovest Global Inc is to acquire existing companies in a select few industries and attract new customers in cost effective ways. Currently, Innovest Global Inc has a Commercial & Industrial Division, a Biotechnology & Health Services Division, and a Construction & Building Materials Division.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter and Facebook @innovestglobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact Information
Corporate Office:
(216) 815-1122
info@innovestglobal.com
Twitter @innovestglobal
Investor Relations:
Hayden IR
(917) 658-7878
hart@haydenir.com
